Emprumapimod

N/A

Report date: 2022/08/29 20:00:24
NME

Base Information

Drug NameEmprumapimod
Drug Alias NameARRY-797ARRY-371797PF-06802861PF-07265803
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitors
TargetsP38 mitogen-activated protein kinase
Therapy Area/IndicationsCardiomyopathy, DilatedToothacheOsteoarthritis, Knee +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncArray Biopharma Inc
Active IndicationsN/A
Inactive IndicationsCardiomyopathy, DilatedToothacheOsteoarthritis, Knee +[5] 

Other Information

ATC CodeN/A
Related LinksN/A